Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	118.33M
Revenue (ttm)	398.00M
Net Income (ttm)	-71.10M
Shares Out	68.01M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,754,865
Open	1.890
Previous Close	1.880
Day's Range	1.740 - 1.890
52-Week Range	1.575 - 25.480
Beta	-0.69
Analysts	Buy
Price Target	5.20 (+198.85%)
Earnings Date	Aug 8, 2024

About AMLX

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 384
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX

Analyst Forecast

According to 7 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is $5.2, which is an increase of 198.85% from the latest price.

Price Target

$5.2

(198.85% upside)

Analyst Consensus: Buy